Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer

Cancer

Volumn 118, Issue 17, 2012, Pages 4309-4320

  Sanoff, Hanna K ^a   Carpenter, William R ^b   Freburger, Janet ^b   Li, Ling ^c   Chen, Kun ^c   Zullig, Leah L ^b   Goldberg, Richard M ^b   Schymura, Maria J ^d   Schrag, Deborah ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b IL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

Author keywords

adjuvant chemotherapy; colon cancer; elderly; oxaliplatin; toxicity

Indexed keywords

FLUOROURACIL; OXALIPLATIN;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COHORT ANALYSIS; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG INDUCED DISEASE; EMERGENCY CARE; FEMALE; HOSPITALIZATION; HUMAN; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MONOTHERAPY; NEUROPATHY; NEUTROPENIA; OBSERVATIONAL STUDY; OUTPATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; REFERENCE DATABASE; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POPULATION SURVEILLANCE;

EID: 84864029042     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27422     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004; 22: 1797-1806.
3. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990; 264: 1444-1450.
4. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27: 3109-3116.
5. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 2343-2351.
6. Bjarnason NH,. Disparities in participation in cancer clinical trials [letter]. JAMA. 2004; 292: 922; author reply 922- 923.
7. Murthy VH, Krumholz HM, Gross CP,. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291: 2720-2726.
8. Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010; 303: 1037-1045.
9. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40 (8 suppl): IV-3-IV-18.
10. National Cancer Institute. SEER-Medicare: Brief Description of the SEER-Medicare Database. Bethesda, MD: National Cancer Institute; 2011 Available from: http://healthservices.cancer.gov/seermedicare/overview/. Accessed May 24, 2011.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
12. Klabunde CN, Potosky AL, Legler JM, Warren JL,. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
13. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
14. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345: 1091-1097.
15. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006; 24: 4085-4091.
16. McCleary NAJ, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients with stage II/III colon cancer: findings from the ACCENT database [abstract]. J Clin Oncol. 2009; 27 (15S). Abstract 4010.
17. Rubin DB,. Estimating causal effects form large data sets using propensity scores. Ann Intern Med. 1997; 127: 757-763.
18. Parsons LS,; Ovation Research Group. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Seattle, WA: Ovation Research Group; 2001. Available from: http://www2.sas.com/proceedings/sugi26/ p214-26.pdf. Accessed August 1, 2011.
19. Sanoff H, Carpenter W, Martin C, et al. Effectiveness of oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst. In press.
20. Handel DA, McConnell KJ, Wallace N, Gallia C,. How much does emergency department use affect the cost of Medicaid programs? Ann Emerg Med. 2008; 51: 614-621.
21. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006; 24: 2368-2375.
22. Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol. 2005; 16: 549-557.
23. Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earle CC, Begg CB,. Measuring complications of cancer treatment using the SEER-Medicare data. Med Care. 2002; 40 (8 suppl): IV-62-IV-68.